Drug intelligence / Profile preview

Ad26.ZIKV.001

Development stage: Phase 1
Lead developer: Janssen Pharmaceutical
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Ad26.ZIKV.001 is a prophylactic vaccine candidate developed to prevent Zika virus (ZIKV) infection. It is a replication-incompetent human adenovirus serotype 26 (Ad26) vector encoding the Zika virus membrane and envelope (M-Env) proteins. The vaccine works by inducing neutralizing antibodies and robust cellular immune responses against Zika virus, aiming to provide protection from infection and its complications, such as congenital Zika syndrome. In phase 1 clinical trials, Ad26.ZIKV.001 demonstrated a favorable safety profile with mild to moderate reactogenicity and induced persistent neutralizing antibody responses in healthy adults. The developer of this vaccine is Janssen Vaccines & Prevention B.V., part of Johnson & Johnson.

Other names: Ad26.ZIKV.M-EnvAd-26.ZIKV.M-EnvAd 26.ZIKV.M-Env

Beyond the preview

Go deeper on Ad26.ZIKV.001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ad26.ZIKV.001.

Explore the full profile